Skip to main content

Overcoming Resistance To Egfr Inhibitors In Egfr Mutant Nsclc

In Order to Read Online or Download Overcoming Resistance To Egfr Inhibitors In Egfr Mutant Nsclc Full eBooks in PDF, EPUB, Tuebl and Mobi you need to create a Free account. Get any books you like and read everywhere you want. Fast Download Speed ~ Commercial & Ad Free. We cannot guarantee that every book is in the library!

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC Book
Author : Anthony Faber
Publisher : Academic Press
Release : 2021-03-15
ISBN : 9780128228333
Language : En, Es, Fr & De

GET BOOK

Book Description :

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC, Volume 17 presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer. Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors Encompasses the current state of affairs in clinical trials to address resistance

Acquired Resistance to Targeted Therapy in EGFR mutant Lung Adenocarcinoma

Acquired Resistance to Targeted Therapy in EGFR mutant Lung Adenocarcinoma Book
Author : Caroline Amalia Nebhan
Publisher : Unknown
Release : 2014
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Acquired Resistance to Targeted Therapy in EGFR mutant Lung Adenocarcinoma book written by Caroline Amalia Nebhan, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Third Generation EGFR Inhibitors

Third Generation EGFR Inhibitors Book
Author : Harun M. Patel,Rahul Pawara,Sanjay J. Surana
Publisher : Elsevier
Release : 2018-11-27
ISBN : 0081026625
Language : En, Es, Fr & De

GET BOOK

Book Description :

Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the development of both covalent irreversible and covalent reversible EGFR Inhibitors. In addition, mechanisms of resistance to third generation inhibitors, and discovery of fourth generation allosteric C797S inhibitors are explored before a discussion of potential future trends. This comprehensive coverage of the design and development of improved analogues to overcome the problems of resistance and toxicity associated with third generation EGFR inhibitors makes Third Generation EGFR Inhibitors a crucial resource for medicinal chemists, drug developers, and researchers investigating cancer therapeutics. Includes full synthetic schemes of all approved and in-trial third generation inhibitors Highlights the emergence of fourth generation EGFR inhibitors and the possibilities of them overcoming constraints of third generation compounds Provides a structural correlation of third and fourth generation EGFR inhibitors, reviewing both their design strategies and typical anticancer activity

Targeted Therapies in Lung Cancer Management Strategies for Nurses and Practitioners

Targeted Therapies in Lung Cancer  Management Strategies for Nurses and Practitioners Book
Author : Marianne Davies,Beth Eaby-Sandy
Publisher : Springer
Release : 2019-07-16
ISBN : 3030165507
Language : En, Es, Fr & De

GET BOOK

Book Description :

This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.

Exploitation and Mechanistic Validation of Drug combination Strategies to Overcome EGFR inhibitor Resistance in NSCLC Cells

Exploitation and Mechanistic Validation of Drug combination Strategies to Overcome EGFR inhibitor Resistance in NSCLC Cells Book
Author : Yu-Chieh Wang
Publisher : Unknown
Release : 2008
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Abstract: Pre-existing and acquired resistance to epidermal growth factor receptor (EGFR) inhibitors limits their clinical usefulness in patients with advanced non-small cell lung cancer (NSCLC). In this dissertation research work, the in vitro/in vivo efficacy and mechanisms of the combination of gefitinib or erlotinib with OSU-03012, a celecoxib-derived antitumor agent, to overcome EGFR inhibitor-resistance in three NSCLC cell lines, H1155, H23, and A549, are characterized. The OSU-03012/EGFR inhibitor combination induced pronounced apoptosis in H1155 and H23 cells, but not in A549 cells, suggesting a correlation between drug sensitivity and basal phospho-Akt levels independently of EGFR expression status. Evidence indicates that this combination facilitates apoptosis through both Akt signaling inhibition and upregulation of ER stress-induced, GADD153-mediated pathways. For example, ectopic expression of constitutively active Akt significantly attenuated the inhibitory effect on cell survival, and siRNA-mediated knockdown of GADD153 protected cells from undergoing apoptosis in response to drug co-treatments. Furthermore, the OSU-03012/EGFR inhibitor combination induced GADD153-mediated upregulation of death receptor 5 expression and subsequent activation of the extrinsic apoptosis pathway. It is noteworthy that the ER stress response induced by this combination was atypical in that the cytoprotective pathway was not engaged. In addition, in vivo suppression of tumor growth and modulation of intratumoral biomarkers were observed in a H1155 tumor xenograft model in nude mice. These data suggest that the concomitant modulation of Akt and ER stress pathways with the OSU-03012/EGFR inhibitor combination represents a unique approach to overcoming EGFR inhibitor resistance in NSCLC and perhaps other types of cancer with elevated basal Akt activities. In addition to the OSU-03012/EGFR inhibitor combinations, erlotinib in combination with HDAC inhibitor vorinostat or OSU-HDAC42 exhibits significantly enhanced anticancer activity in two EGFR-inhibitor resistant NSCLC cell lines, H1299 and H1975, by targeting signaling involved in regulation of cell survival and death at multiple levels. The erlotinib/HDAC inhibitor combination elicited massive apoptosis in both of H1299 and H1975 cell lines, suggesting that the anticancer activity of this combination strategy is independent of p53 function and EGFR mutations. Evidence indicates that this combination facilitates apoptosis through inhibition of Akt and Erk survival signaling and activation of NR4A1-mediated apoptosis. The studies presented here provide novel mechanistic rationales for the clinical use of EGFR inhibitors to possibly form more effective protocols for treating NSCLC patients.

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies Book
Author : Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
Publisher : Springer
Release : 2019-07-15
ISBN : 303021477X
Language : En, Es, Fr & De

GET BOOK

Book Description :

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.

AACR 2016 Abstracts 1 2696

AACR 2016  Abstracts 1 2696 Book
Author : American Association for Cancer Research (AACR)
Publisher : CTI Meeting Technology
Release : 2016-03-28
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

The AACR Annual Meeting is a must-attend event for cancer researchers and the broader cancer community. This year's theme, "Delivering Cures Through Cancer Science," reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are presented in every area of cancer research. There will be a number of presentations that include exciting new data from cutting-edge clinical trials as well as companion presentations that spotlight the science behind the trials and implications for delivering improved care to patients. This book contains abstracts 1-2696 presented on April 17-18, 2016, at the AACR Annual Meeting.

IASLC Thoracic Oncology E Book

IASLC Thoracic Oncology E Book Book
Author : Harvey Pass,David Ball,Giorgio Scagliotti
Publisher : Elsevier Health Sciences
Release : 2017-04-21
ISBN : 0323527841
Language : En, Es, Fr & De

GET BOOK

Book Description :

Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today’s best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies. Offers practical, relevant coverage of basic science, epidemiology, pulmonology, medical and radiation oncology, surgery, pathology, palliative care, nursing, and advocacy. Provides authoritative guidance from the IASLC – the only global organization dedicated to the study of lung cancer. Includes new content on molecular testing, immunotherapy, early detection, staging and the IASLC staging system, surgical resection for stage I and stage II lung cancer, and stem cells in lung cancer. Features a new full-color design throughout, as well as updated diagnostic algorithms.

Second Line Treatment of Non Small Cell Lung Cancer Clinical Pathological and Molecular Aspects of Novel Promising Drugs

Second Line Treatment of Non Small Cell Lung Cancer  Clinical  Pathological and Molecular Aspects of Novel Promising Drugs Book
Author : Umberto Malapelle,Pierlorenzo Pallante
Publisher : Frontiers Media SA
Release : 2017-08-29
ISBN : 2889452638
Language : En, Es, Fr & De

GET BOOK

Book Description :

Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therapeutic options are reserved to a minor part of lung cancer patients harbouring specific mutations. In the so called wild type population, the first line options bring the median overall survival to go beyond 1 year, and in the population receiving the maintenance therapy over 16 months. Given these results, more than 60% of patients may receive a second line therapy with further opportunities to improve the length and quality of life. For patients not harbouring targetable DNA mutations newer options will be available for second line therapeutic schemes and two major assets seem to be promising: immune modulation and anti-angiogenetic agents. In particular, anti PD1/PDL1 antibodies, VEGFR antibodies and TKIs, these latter combined with standard chemotherapy docetaxel advance the median overall survival of 12 months. These drugs have a different mechanism of action, various adverse events and their activity is different depending on the types of population. However, the biomarkers’ activity and efficacy prediction are not fully or totally understood. In addition, also for patients with DNA targetable mutations new drugs seems to be promising for the use in the second line therapeutic protocols. In particular, drugs selectively directed against ALK translocation and mutational events and EGFR T790M secondary mutations seems to be very promising. In this Research Topic we critically discuss the older therapies and the historical development of second line, putting in to perspective the new agents available in clinical practice. We discuss their importance from a clinical point of view, but also consider and exploit the complex molecular mechanisms responsible of their efficacy or of the subsequently observed resistance phenomena. In this perspective, the undercovering and characterization of novel predictive biomarkers by NGS technology, the characterization of novel actors in the signal transduction pathway modulating the response of the cells, the optimization of new diagnostic tool as the evaluation of liquid biopsy and the implementation of more suitable pre-clinical models are crucial aspects dissected too. Nivolumab, nintedanib and ramucirumab probably will give the opportunity to improve the efficacy outcomes for the treatment of wild type tumours in second line therapeutic schemes, but many aspects should be debated in order that these agents are made available to patients, planning ahead a therapeutic strategy, beginning from the first line therapy, to the subsequent ones in a logical and affordable manner. As well, for treatment of mutated tumours, mutated EGFR irreversible inhibitors such as rociletinib and AZD9291, and ALK targeting drugs ceritinib and alectinib will also play an important role in the immediate future. Probably the right way is to give all the available opportunities to patients, but challenges and pitfalls should be carefully debated, and by launching this Research Topic we tried to give some practical insights in this changing landscape.

Cancer Research

Cancer Research Book
Author : Anonim
Publisher : Unknown
Release : 2008
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Cancer Research book written by , available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

The Treatment of Metastatic Non small Cell Lung Cancer NSCLC in New Era of Personalised Medicine

The Treatment of Metastatic Non small Cell Lung Cancer  NSCLC  in New Era of Personalised Medicine Book
Author : Vera Hirsh,Barbara Melosky
Publisher : Frontiers Media SA
Release : 2015-10-20
ISBN : 2889195430
Language : En, Es, Fr & De

GET BOOK

Book Description :

Lung cancer is the leading cause of cancer related mortality in Canada and USA. Majority of the patients present in advanced stage of the disease and of these only about 2% will be alive at 5 years. NSCLC is the most common form of lung cancer, accounting for approximately 87% of cases. Systemic chemotherapies have been used to treat metastatic NSCLC for decades, but the improvements of outcomes have reached a plateau. Recent advances in understanding signalling pathways for malignant cells, their interconections,the importance of various receptors and biomarkers and the interplay between various oncogenes have led to the development of targeted treatments that are improving both efficacy and safety of the treatments. Knowledge about the advantages of treatments with the targeted agents in metastatic NSCLC is growing rapidly. Combining various targeted agents or sequencing them properly will be important in the era of personalised medicine and overcoming development of the resistence to various targeted agents will be challenging. The importance of a team work,from the diagnosis through various treatments, to supportive care, from the interventional radiologists, pneumologists or surgeons, who have to obtain a satisfactory tumor tissue specimen, to pathologists, radiation and medical oncologists, to supportive care specialists, will be described in our publications. We will cover completely present and future approaches to personalised medicine in this rapidly evolving field of metastatic NSCLC.

Molecular Targeted Therapy of Lung Cancer

Molecular Targeted Therapy of Lung Cancer Book
Author : Yuichi Takiguchi
Publisher : Springer
Release : 2017-01-24
ISBN : 9811020027
Language : En, Es, Fr & De

GET BOOK

Book Description :

This book discusses the latest molecular targeted therapy of lung cancer including its evaluation and future directions. It clearly illustrates the initial dramatic effectiveness of molecular targeted therapy, recurrence of the disease, overcoming the wide variety of resistance mechanisms using new-generation molecular targeted agents and potential novel approaches. It also outlines the increasing necessity for new diagnostic technology and strategies for managing different adverse effects and novel methods for evaluating effectiveness and safety. Edited and authored by opinion leaders, Molecular Targeted Therapy of Lung Cancer provides a comprehensive overview of the disease and its treatments. It is a valuable resource for graduate students, post-doctoral fellows and faculty staff, as well as researchers involved in clinical and translational research on lung cancer, helping promote new ideas for further advances.

Oncology

Oncology Book
Author : Anonim
Publisher : Unknown
Release : 2008
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Oncology book written by , available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

At 101 Enhances Gefitinib Sensitivity in Non Small Cell Lung Cancer with EGFR T790M Mutations

At 101 Enhances Gefitinib Sensitivity in Non Small Cell Lung Cancer with EGFR T790M Mutations Book
Author : Cape Town Cape Town Press
Publisher : Unknown
Release : 2017-01-03
ISBN : 9781542336659
Language : En, Es, Fr & De

GET BOOK

Book Description :

Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have become the standard care of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), development of acquired resistance is inevitable. A secondary mutation of threonine 790 (T790M) is associated with approximately half of the cases of acquired resistance. Strategies or agents to overcome this type of resistance are still limited. In this study, enhanced antitumor effect of AT-101, a-pan-Bcl-2 inhibitor, on gefitinib was explored in NSCLC with T790M mutation. Proceeds from the sale of this book go to support an elderly disabled person.

American Journal of Respiratory and Critical Care Medicine

American Journal of Respiratory and Critical Care Medicine Book
Author : Anonim
Publisher : Unknown
Release : 2007
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download American Journal of Respiratory and Critical Care Medicine book written by , available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Compendium of Awards

Compendium of Awards Book
Author : Tobacco-Related Disease Research Program (University of California (System))
Publisher : Unknown
Release : 2002
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Compendium of Awards book written by Tobacco-Related Disease Research Program (University of California (System)), available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

From NF B to FACT

From NF   B to FACT Book
Author : Josephine Kam Tai Dermawan
Publisher : Unknown
Release : 2015
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

The epidermal growth factor receptor (EGFR) drives downstream signaling pathways that promote cancer progression. EGFR is often constitutively active in tumors, e.g., non-small cell lung cancer (NSCLC) and glioblastoma (GBM), either by overexpression or mutations. Nuclear factor-¿B (NF-¿B) is a master transcription factor that controls inflammation and innate immunity. NF-¿B, often constitutively activated in cancer, drives tumor development by activating antiapoptotic and prosurvival genes, and has been implicated in anticancer drug resistance. We and others have shown that EGFR activates NF-¿B signaling in both noncancerous and cancer cells. In an attempt to overcome drug resistance to EGFR tyrosine kinase inhibitors (TKI): erlotinib and lapatinib in NSCLC and GBM respectively, we combined EGFR-TKI with a novel class of NF-¿B inhibitors, including quinacrine and curaxins, which inhibit NF-¿B-driven transcription by targeting the facilitates chromatin transcription (FACT) complex. Unexpectedly, we discovered preferential targeting of GBM stem cells (GSCs), another major player in cancer therapeutic resistance, by curaxins, uncovering a potential role of FACT in the maintenance of stem cell phenotypes. Beyond applications in anticancer therapeutics, we are interested in the basic biological question of how EGFR, compared to canonical NF-¿B activators such as interleukin 1 (IL-1), regulates NF-¿B distinctively. Specifically, we utilize genomic approaches including RNA-sequencing (RNA-sequencing) and chromatin immunoprecipitation (ChIP)-sequencing to investigate the signal-specific, genome-wide regulation of NF-¿B-driven transcription by EGFR versus IL-1. One possible mechanism that underlies specificity in transcription factor regulation is differential phosphorylation. We speculate that phosphorylation of the serine 276 residue on the NF-¿B subunit p65 (RELA) plays a role in EGFR-mediated NF-¿B regulation. Using the gene editing approach CRISPR, we have introduced the genetic mutation S276A in the RELA gene. In the next phase, we plan to interrogate the impact of this mutation in EGFR-mediated NF-¿B regulation. In addition, we will interrogate whether STAT3, a major oncogene also activated by EGFR, serves as a transcriptional coregulator in the context of NF-¿B-driven transcription. Taken together, these studies elucidate how EGFR regulates NF-¿B on a genomic level, which remains poorly understood, and have major implications in anticancer therapy and drug resistance, especially in cancers driven by EGFR and/or NF-¿B.

Targeted Therapies in Lung Cancer

Targeted Therapies in Lung Cancer Book
Author : Marianne Davies,Beth Eaby-Sandy
Publisher : Unknown
Release : 2019
ISBN : 9783030165529
Language : En, Es, Fr & De

GET BOOK

Book Description :

This book aims to educate nurses and advanced practice providers (APP's) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP's are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP's with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.

Annual Meeting Proceedings

Annual Meeting Proceedings Book
Author : American Society of Clinical Oncology. Meeting
Publisher : Unknown
Release : 2008
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Annual Meeting Proceedings book written by American Society of Clinical Oncology. Meeting, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Therapeutic Strategies to Overcome ALK Resistance in Cancer

Therapeutic Strategies to Overcome ALK Resistance in Cancer Book
Author : Luc Friboulet
Publisher : Academic Press
Release : 2021-01-18
ISBN : 0128217790
Language : En, Es, Fr & De

GET BOOK

Book Description :

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment. Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality Presents an overview of current treatments and the benefits of ALK TKI in lung and other cancer types, such as ALCL, neuroblastoma and inflammatory myofibroblastic tumor Encompasses information on systemic treatments other than TKI, including chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC